NASDAQ · BNTC
Healthcare · Biotechnology
$9.00
Up+$0.17 (+1.93%)
Updated Oct 7, 2026, 3:29 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BNTC
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
BNTC closed at $9.00 after 21 trading sessions, down 29.27% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $9.32 | $9.565 | $8.62 | $9.00 | 217.15K |
| Oct 5, 2026 | $9.00 | $9.99 | $8.52 | $9.23 | 584.24K |
| Oct 2, 2026 | $9.71 | $9.8761 | $8.92 | $8.98 | 135.14K |
| Oct 1, 2026 | $9.94 | $10.17 | $9.465 | $9.58 | 103.1K |
| Sep 30, 2026 | $9.83 | $10.13 | $9.64 | $10.00 | 145.99K |
| Sep 29, 2026 | $10.17 | $10.17 | $9.65 | $9.75 | 110.97K |
| Sep 28, 2026 | $9.57 | $10.04 | $9.31 | $10.02 | 152.79K |
| Sep 25, 2026 | $9.70 | $9.80 | $9.3056 | $9.59 | 106.97K |
| Sep 24, 2026 | $9.74 | $10.41 | $9.255 | $9.64 | 196.78K |
| Sep 23, 2026 | $10.92 | $11.32 | $9.49 | $9.83 | 644.18K |
| Sep 22, 2026 | $10.97 | $11.365 | $10.61 | $10.95 | 88.93K |
| Sep 21, 2026 | $11.12 | $11.14 | $10.74 | $10.88 | 121.92K |
| Sep 18, 2026 | $11.37 | $11.62 | $10.86 | $11.02 | 422.99K |
| Sep 17, 2026 | $11.27 | $11.55 | $11.15 | $11.36 | 91.25K |
| Sep 16, 2026 | $11.09 | $11.4503 | $10.89 | $11.04 | 138.83K |
| Sep 15, 2026 | $12.11 | $12.37 | $10.96 | $11.05 | 263.43K |
| Sep 14, 2026 | $12.24 | $12.415 | $12.01 | $12.08 | 106.38K |
| Sep 11, 2026 | $12.38 | $12.505 | $12.12 | $12.19 | 88.59K |
| Sep 10, 2026 | $12.31 | $12.47 | $12.00 | $12.22 | 94.59K |
| Sep 9, 2026 | $12.68 | $12.995 | $12.22 | $12.45 | 69.99K |
| Sep 8, 2026 | $12.55 | $13.00 | $12.5061 | $12.725 | 102.2K |
The latest Smart Investors Daily articles mentioning BNTC.
Company
Market Activity
Research & News
BNTC research
Company profile and research snapshot.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 15, 2026 | Wedbush | Outperform | — |
| Jul 28, 2026 | Wedbush | Outperform | — |
| May 12, 2026 | Evercore ISI Group | Outperform | — |
| Mar 9, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 24, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 25, 2026
Benitec Biopharma (BNTC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Benzinga · Sep 15, 2026
Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $16 to $17.
Yahoo · Sep 14, 2026
All six Cohort 1 (low dose BB-301) patients have completed the full 12-month post-treatment follow-up period, and Cohort 2 (high dose BB-301) is fully enrolled with all three patients having been safely treatedA Type C meeting was held with the U.S. Food and Drug Administration in 3Q2026 to discuss the BB-301 pivotal study design, and meeting minutes are anticipated in OctoberAdditional interim clinical study results from the ongoing BB-301 Phase 1b/2a trial have been accepted for late-breaking
Benzinga · Sep 14, 2026
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 38.1 percent increase over losses of $(0.42) per share from the same period last year.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BNTC.
